DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

BTIG Research Maintains Buy on Intra-Cellular Therapies, Lowers Price Target to $68

BTIG Research maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and lowers the price target from $73 to $68.

Benzinga · 03/03/2020 12:52

BTIG Research maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and lowers the price target from $73 to $68.